Table 1.
Registered clinical trials that investigate the combination of CD47/SIRPα blockade together with T cell immune checkpoint PD-1/PD-L1 blockade
| Drugs | Phase | Clinical trial identifier | Status | Tumor type |
| HX009; recombinant anti-CD47/PD-1 bispecific antibody | II | NCT04886271 | Recruiting | Advanced solid tumors |
| I | NCT04097769 | Active, not recruiting | Advanced solid tumors | |
| PF-07257876; bispecific anti-CD47/PD-L1 antibody | I | NCT04881045 | Not yet recruiting | Advanced solid tumors |
| TTI-621 (SIRPα-IgG1 Fc)+nivolumab | I | NCT02663518 | Recruiting | Hematological and solid tumors |
| TTI-621+PD-1/PD-1 blockade | I | NCT02890368 | Terminated | Advanced solid tumors and mycosis fungoides |
| Anti-CD47 AO-176+pembrolizumab | I/II | NCT03834948 | Recruiting | Solid tumors |
| IBI322; recombinant anti-CD47/PD-1 bispecific antibody | I | NCT04912466 | Not yet recruiting | Advanced solid malignancies |
| I | NCT04795128 | Recruiting | Hematological malignancies | |
| I | NCT04338659 | Not yet recruiting | Advanced solid malignancies | |
| I | NCT04328831 | Recruiting | Advanced malignancies | |
| Magrolimab and pembrolizumab | II | NCT04788043 | Not yet recruiting | Advanced classic Hodgkin’s lymphoma |
| ALX148+pembrolizumab | I | NCT03013218 | Active, not recruiting | Advanced hematological and solid tumors |
| ALX148+pembrolizumab | II | NCT04675294 | Recruiting | Advanced head and neck squamous cell carcinoma |
| BI-765063 (anti-SIRPα)+BI-754091 (anti-PD-1) | I | NCT03990233 | Recruiting | Advanced solid tumors |
| BI-76503 (anti-SIRPα)+BI-75491 (anti-PD-1) | NCT04653142 | Recruiting | Advanced solid tumors |
CD47, cluster of differentiation 47; PD-1, programmed death receptor 1; PD-L1, programmed death ligand 1; SIRPα, signal regulatory protein alpha.